GE Healthcare is touting studies of its investigational F-18 flutemetamol PET imaging agent that were presented at the Society of Nuclear Medicine (SNM) annual meeting.
In a comparison of automated quantification methods using 72 images from an F-18 flutemetamol phase II study, a PET-only method produced very similar results to an MR-based method using FreeSurfer reconstruction software, according to the vendor. In addition, the automated PET-only method yielded similar results to those obtained when a trained expert manually placed regions on coregistered MRI scans, GE said.
Two phase I studies in healthy Japanese volunteers and in subjects with probable Alzheimer's disease both showed that radiation dosimetry profiles in healthy volunteers were comparable to those of most PET diagnostic radiopharmaceuticals, GE said. The studies also showed that biodistribution attributes were similar in Japanese and Caucasian populations of healthy volunteers and patients with probable Alzheimer's disease.
In another study involving 11 community-dwelling, nondemented older adults with subjective memory complaints, F-18 flutemetamol uptake showed a significant negative correlation when the delayed memory index was adjusted for premorbid IQ, GE said.
